Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmaco-epidemiological Study on the Effect of Retacrit on Chemotherapy Induced Anaemia in Standard Oncology and Haematology Practice: Impact of Concomitant Iron Supplementation

Trial Profile

Pharmaco-epidemiological Study on the Effect of Retacrit on Chemotherapy Induced Anaemia in Standard Oncology and Haematology Practice: Impact of Concomitant Iron Supplementation

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Apr 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Epoetin zeta (Primary)
  • Indications Chemotherapy-induced anaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SYNERGY
  • Sponsors Hospira
  • Most Recent Events

    • 11 Jul 2016 New source identified and integrated ClinicalTrials.gov: US National Institutes of Health: (NCT02158169)
    • 07 Jun 2016 Results of sub-analysis of patients with hematological malignancies (n=423) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 07 Jun 2016 Results (subanalysis, n = 1657) assessing efficacy of epoetin zeta in patients with solid tumors presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top